Background/aims: The mitotic kinesin superfamily protein KIF14 is essential for cytokinesis and chromosome segregation, and increased KIF14 expression is related to a variety of human cancers. However, the role of KIF14 in the development and malignant progression of astrocytomas and the underlying mechanisms remain unclear. The present study examined the relation between KIF14 and the pathogenesis of malignant astrocytoma.
Methods And Results: The role of KIF14 in astrocytoma development and progression was investigated by analyzing KIF14 expression using SYBR Green quantitative real-time RT-PCR, western blotting and immunohistochemistry in human astrocytoma and normal brain tissues. KIF14 expression was higher in astrocytoma samples, and was positively correlated with pathological grade and proliferative activity indicated by Ki-67 staining. SiRNA knockdown of KIF14 inhibited tumor growth in vitro and in vivo, attenuated anchorage-independent growth, and induced G2/M phase arrest, cytokinesis failure and apoptosis in glioblastoma cell lines in association with decreased AKT phosphorylation and activity.
Conclusions: The upregulation of KIF14 in astrocytoma is associated with disease severity, and suppression of KIF14 inhibits cell proliferation and induces apoptosis through a mechanism involving the inactivation of AKT signaling, suggesting that KIF14 plays an important role in astrocytoma tumorigenesis and could be a promising molecular target for anticancer therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000438532 | DOI Listing |
Cancers (Basel)
October 2024
Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USA.
: Breast cancer is diagnosed in 2.3 million women each year and kills 685,000 (~30% of patients) worldwide. The prognosis for many breast cancer subtypes has improved due to treatments targeting the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).
View Article and Find Full Text PDFCancer Rep (Hoboken)
August 2024
Department of Molecular Genetics, Ahar Branch, Islamic Azad University, Ahar, Iran.
Background: Hepatocellular carcinoma (HCC) represents a primary liver tumor characterized by a bleak prognosis and elevated mortality rates, yet its precise molecular mechanisms have not been fully elucidated. This study uses advanced bioinformatics techniques to discern differentially expressed genes (DEGs) implicated in the pathogenesis of HCC. The primary objective is to discover novel biomarkers and potential therapeutic targets that can contribute to the advancement of HCC research.
View Article and Find Full Text PDFMediterr J Hematol Infect Dis
July 2024
Department of Medical Biology, Faculty of Medicine, Ankara University, Ankara, Turkey.
Background: Acute myeloid leukaemia (AML) is a disease of the haematopoietic stem cells(HSCs) that is characterised by the uncontrolled proliferation and impaired differentiation of normal haematopoietic stem/progenitor cells. Several pathways that control the proliferation and differentiation of HSCs are impaired in AML. Activation of the Wnt/beta-catenin signalling pathway has been shown in AML and beta-catenin, which is thought to be the key element of this pathway, has been frequently highlighted.
View Article and Find Full Text PDFGene
November 2024
Department of Gynaecology and Obstetrics, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China. Electronic address:
Objectives: The study aims to investigate genes associated with endometrial cancer (EC) progression to identify new biomarkers for early detection.
Methods: Differentially expressed genes (DEGs), Series test of cluster (STC) and protein-protein interaction analyses identified hub genes in EC. Clinical samples were utilized to examine the expression pattern of ECT2, assess its prognostic value, and evaluate its diagnostic potential.
Sci Rep
July 2024
Department of Orthopaedic and Trauma, The Affiliated Hospital of Yunnan University, Kunming, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!